I'm LongbridgeAI, I can summarize articles.Goldman Sachs published a research report saying that China's CRO and CDMO companies delivered solid results in the third quarter. Despite continued negative impact from foreign exchange factors, momentum in new orders remained strong, coupled with accelerated capacity expansion, which is expected to provide greater visibility for manufacturing businesses next year. Improved biotech financing, M&A and business development activities, as well as emerging AI-driven drug discovery activities, also supported rising demand for wet labs.
The broker noted that WUXI APPTEC (02359.HK) +3.400 (+1.729%) Short selling $321.20M; Ratio 37.098% 's new orders in the first three quarters of this year accelerated to about 60% YoY, while PHARMARON (03759.HK) +0.200 (+0.674%) Short selling $9.97M; Ratio 14.757% recorded around 30% growth in the third quarter, TIGERMED (03347.HK) -0.560 (-1.452%) Short selling $1.62M; Ratio 8.303% posted growth close to 30%, and ASYMCHEM (06821.HK) +1.200 (+0.970%) Short selling $2.48M; Ratio 3.985% also maintained around 30% growth. Updated guidance was broadly in line with the broker's expectations. Among them, WUXI APPTEC (02359.HK) +3.400 (+1.729%) Short selling $321.20M; Ratio 37.098% raised its 2026 continuing operations revenue growth guidance to 40% to 42%, while its capital expenditure budget continued to advance.
Following the recent pullback in share prices of China's CRO and CDMO sector, Goldman Sachs believed the weakness instead created better positioning opportunities. WUXI APPTEC (02359.HK) +3.400 (+1.729%) Short selling $321.20M; Ratio 37.098% being removed from the US Department of Defense's 1260H list reduced the risk of being included in the preliminary BCC list through that route. The broker believed short-term risks related to the Biosecure Act had eased, although geopolitical developments could still bring volatility to share prices.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-12 12:25.)
